Atlas Trials

A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Clinical trial NCT07462468 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07462468
Sponsor
WestVac Biopharma Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Platinum-resistant Recurrent Ovarian Cancer (PROC)
Start date
2026-03-10
Primary completion
2027-03-31
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.